Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 1997

View Archived Issues

Relaxin-like factor and relaxin analogues described

Novel rapamycin derivatives reported by Novartis

Alcon describes dihydropyridines for ocular use

Fibrinogen antagonists from Glaxo Wellcome

Sanofi Winthrop reveals calpain inhibitors

Novel vasopressin antagonists from Fujisawa

Novel anti-HIV agent reported by Belgian and Mauritian researchers

Antisense compound for asthma shows promise

Alpha-Beta/MycoTox antifungal collaboration

ARIAD and Genovo form gene therapy joint venture

Seragen begins to restructure, sells manufacturing/clinical operations facility

Immunex clones and describes target for RA

National Patent/PolyMASC extend cancer vaccine collaboration

MAA filed for Agouron anti-HIV drug

Cylexin enters clinical trials in newborns

Transdermal buspirone pivotal trials

Antiadhesion product enters clinical trials

Oncogen Science stock changes hands

Multinational clinical trial results for Zenapax

Centocor seeks expansion of ReoPro indications

Deltibant in SIRS

Positive clinical results for doxazosin as BPH Rx

Comparative trial of dorzolamide and acetazolamide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...